AbCellera Biologics Inc.

2.42
0.03 (1.26%)
At close: Apr 17, 2025, 3:59 PM
2.41
-0.41%
After-hours: Apr 17, 2025, 06:43 PM EDT

AbCellera Biologics Statistics

Share Statistics

AbCellera Biologics has 297.99M shares outstanding. The number of shares has increased by 1.34% in one year.

Shares Outstanding 297.99M
Shares Change (YoY) 1.34%
Shares Change (QoQ) 0.89%
Owned by Institutions (%) 38.62%
Shares Floating 202.8M
Failed to Deliver (FTD) Shares 12.36K
FTD / Avg. Volume 0.29%

Short Selling Information

The latest short interest is 23.62M, so 7.93% of the outstanding shares have been sold short.

Short Interest 23.62M
Short % of Shares Out 7.93%
Short % of Float 10.27%
Short Ratio (days to cover) 7.13

Valuation Ratios

The PE ratio is -5.3 and the forward PE ratio is -3.72. AbCellera Biologics's PEG ratio is -0.68.

PE Ratio -5.3
Forward PE -3.72
PS Ratio 29.91
Forward PS 9.8
PB Ratio 0.82
P/FCF Ratio -4.61
PEG Ratio -0.68
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for AbCellera Biologics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 9.81, with a Debt / Equity ratio of 0.06.

Current Ratio 9.81
Quick Ratio 9.81
Debt / Equity 0.06
Debt / EBITDA -0.3
Debt / FCF -0.32
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $48.38K
Profits Per Employee $-273.25K
Employee Count 596
Asset Turnover 0.02
Inventory Turnover n/a

Taxes

Income Tax -37.54M
Effective Tax Rate 18.73%

Stock Price Statistics

The stock price has increased by -38.11% in the last 52 weeks. The beta is 0.49, so AbCellera Biologics's price volatility has been higher than the market average.

Beta 0.49
52-Week Price Change -38.11%
50-Day Moving Average 2.56
200-Day Moving Average 2.77
Relative Strength Index (RSI) 52.58
Average Volume (20 Days) 4.31M

Income Statement

In the last 12 months, AbCellera Biologics had revenue of 28.83M and earned -162.86M in profits. Earnings per share was -0.55.

Revenue 28.83M
Gross Profit 28.83M
Operating Income -314.77M
Net Income -162.86M
EBITDA -204.15M
EBIT -301.15M
Earnings Per Share (EPS) -0.55
Full Income Statement

Balance Sheet

The company has 156.32M in cash and 60.74M in debt, giving a net cash position of 95.58M.

Cash & Cash Equivalents 156.32M
Total Debt 60.74M
Net Cash 95.58M
Retained Earnings 0
Total Assets 1.36B
Working Capital 674.76M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -108.56M and capital expenditures -78.4M, giving a free cash flow of -186.95M.

Operating Cash Flow -108.56M
Capital Expenditures -78.4M
Free Cash Flow -186.95M
FCF Per Share -0.64
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -1091.69% and -564.83%.

Gross Margin 100%
Operating Margin -1091.69%
Pretax Margin -695.02%
Profit Margin -564.83%
EBITDA Margin -708.04%
EBIT Margin -1091.69%
FCF Margin -648.4%

Dividends & Yields

ABCL does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for ABCL is $7.5, which is 209.9% higher than the current price. The consensus rating is "Buy".

Price Target $7.5
Price Target Difference 209.9%
Analyst Consensus Buy
Analyst Count 3
Stock Forecasts

Scores

Altman Z-Score 1.3
Piotroski F-Score 3